These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

391 related articles for article (PubMed ID: 25630411)

  • 41. Combinations of antimicrobial agents. I. The in vitro sensitivity of 100 strains of Pseudomonas aeruginosa to polymyxin B, colistin, carbenicillin, gentamicin and doxycycline and to various combinations of these antibiotics.
    Kuipers JS
    Arch Chir Neerl; 1975; 27(4):257-70. PubMed ID: 174496
    [TBL] [Abstract][Full Text] [Related]  

  • 42. In vitro Pharmacodynamics and PK/PD in Animals.
    Lee W; Cai Y; Lim TP; Teo J; Chua SC; Kwa AL
    Adv Exp Med Biol; 2019; 1145():105-116. PubMed ID: 31364074
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Combination therapy for carbapenem-resistant Gram-negative bacteria.
    Zavascki AP; Bulitta JB; Landersdorfer CB
    Expert Rev Anti Infect Ther; 2013 Dec; 11(12):1333-53. PubMed ID: 24191943
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Colistin loading dose: evaluation of the published pharmacokinetic and clinical data.
    Vardakas KZ; Rellos K; Triarides NA; Falagas ME
    Int J Antimicrob Agents; 2016 Nov; 48(5):475-484. PubMed ID: 27743779
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Clinical Efficacy of Polymyxin Monotherapy versus Nonvalidated Polymyxin Combination Therapy versus Validated Polymyxin Combination Therapy in Extensively Drug-Resistant Gram-Negative Bacillus Infections.
    Cai B; Cai Y; Liew YX; Chua NG; Teo JQ; Lim TP; Kurup A; Ee PL; Tan TT; Lee W; Kwa AL
    Antimicrob Agents Chemother; 2016 Jul; 60(7):4013-22. PubMed ID: 27090177
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Molecular mechanisms of polymyxin resistance: knowns and unknowns.
    Baron S; Hadjadj L; Rolain JM; Olaitan AO
    Int J Antimicrob Agents; 2016 Dec; 48(6):583-591. PubMed ID: 27524102
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dosing of colistin-back to basic PK/PD.
    Bergen PJ; Li J; Nation RL
    Curr Opin Pharmacol; 2011 Oct; 11(5):464-9. PubMed ID: 21835694
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multidrug-resistant gram-negative infections. Bringing back the old.
    Chan-Tompkins NH
    Crit Care Nurs Q; 2011; 34(2):87-100. PubMed ID: 21407003
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Multidrug-Resistant Gram-negative Superbugs Threat Require Intelligent Use of the Last Weapon.
    Deris ZZ
    Malays J Med Sci; 2015 Sep; 22(5):1-6. PubMed ID: 28239263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical Pharmacokinetics and Pharmacodynamics of Colistin.
    Grégoire N; Aranzana-Climent V; Magréault S; Marchand S; Couet W
    Clin Pharmacokinet; 2017 Dec; 56(12):1441-1460. PubMed ID: 28550595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Local administration of polymyxins into the respiratory tract for the prevention and treatment of pulmonary infections in patients without cystic fibrosis.
    Falagas ME; Kasiakou SK
    Infection; 2007 Feb; 35(1):3-10. PubMed ID: 17297582
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
    Giamarellou H
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combination therapy for carbapenem-resistant Gram-negative bacteria.
    Paul M; Carmeli Y; Durante-Mangoni E; Mouton JW; Tacconelli E; Theuretzbacher U; Mussini C; Leibovici L
    J Antimicrob Chemother; 2014 Sep; 69(9):2305-9. PubMed ID: 24872346
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk factors for acute kidney injury in patients treated with polymyxin B or colistin methanesulfonate sodium.
    Tuon FF; Rigatto MH; Lopes CK; Kamei LK; Rocha JL; Zavascki AP
    Int J Antimicrob Agents; 2014 Apr; 43(4):349-52. PubMed ID: 24439066
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Agents of Last Resort: Polymyxin Resistance.
    Kaye KS; Pogue JM; Tran TB; Nation RL; Li J
    Infect Dis Clin North Am; 2016 Jun; 30(2):391-414. PubMed ID: 27208765
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Polymyxins - review with emphasis on nephrotoxicity].
    Mendes CA; Burdmann EA
    Rev Assoc Med Bras (1992); 2009; 55(6):752-9. PubMed ID: 20191233
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.
    Karaiskos I; Friberg LE; Pontikis K; Ioannidis K; Tsagkari V; Galani L; Kostakou E; Baziaka F; Paskalis C; Koutsoukou A; Giamarellou H
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7240-8. PubMed ID: 26369974
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetics of Polymyxins in Animals.
    Marchand S; Grégoire N; Couet W
    Adv Exp Med Biol; 2019; 1145():89-103. PubMed ID: 31364073
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes.
    Poirel L; Jayol A; Nordmann P
    Clin Microbiol Rev; 2017 Apr; 30(2):557-596. PubMed ID: 28275006
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pharmacokinetics of nebulized colistin methanesulfonate in critically ill patients.
    Boisson M; Grégoire N; Cormier M; Gobin P; Marchand S; Couet W; Mimoz O
    J Antimicrob Chemother; 2017 Sep; 72(9):2607-2612. PubMed ID: 28575278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.